A refined diagnostic algorithm for polycythemia vera that incorporates mutation screening for JAK2(V617F)

Area of Science:

• Hematology
• Molecular Diagnostics
• Oncology

Background:

• Red cell mass (RCM) measurement has historically been used to diagnose polycythemia vera.
• Diagnostic criteria from major organizations have included RCM measurement without robust evidence of its accuracy.
• RCM measurement is recognized as a complex and expensive procedure, leading to its decreased use in clinical practice.

Purpose of the Study:

• To evaluate the diagnostic utility of red cell mass (RCM) measurement for polycythemia vera.
• To advocate for a shift towards biologically-based diagnostic algorithms.
• To highlight the importance of JAK2 mutation screening in contemporary polycythemia vera diagnosis.

Main Methods:

• Review of historical diagnostic criteria for polycythemia vera.
• Assessment of the clinical practicality and cost-effectiveness of RCM measurement.
• Evaluation of the diagnostic impact of the JAK2(V617F) mutation discovery.

Main Results:

• Evidence supporting the diagnostic accuracy of RCM measurement is lacking.
• JAK2(V617F) somatic mutation is a highly prevalent biomarker in polycythemia vera.
• A contemporary diagnostic approach integrates JAK2 mutation status and erythropoietin levels.

Conclusions:

• RCM measurement is an unreliable and impractical diagnostic tool for polycythemia vera.
• Biologically-based diagnostic strategies, including JAK2 mutation screening, are superior.
• Modern diagnosis of polycythemia vera should prioritize molecular and serological markers over RCM measurement.